Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will ...
The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability ...
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) had its price objective increased by equities research analysts at The Goldman Sachs Group from $5.50 to $7.50 in a note issued to investors on ...